Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases: A new therapeutic option

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 752-756

  Yoon, Kam Hon ^a,b,c  

^a Arthritis and Rheumatism Specialist Medical Clinic   (Singapore)

^b CHANGI GENERAL HOSPITAL   (Singapore)

^c Block 102 ^*  (Singapore)

Author keywords

Everolimus; Proliferation signal inhibitors; Rheumatic diseases; Sirolimus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN A; DAPSONE; EVEROLIMUS; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; SALAZOSULFAPYRIDINE; TACROLIMUS;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CHINESE; CLINICAL ARTICLE; CONFERENCE PAPER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INDIAN; MALAYSIA; MALE; POLIOMYELITIS; PSORIATIC ARTHRITIS; RACE DIFFERENCE; RECURRENT DISEASE; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; VASCULITIS;

EID: 69949138951     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04663.x     Document Type: Conference Paper

References (14)

1. Kelly, P.A. et al. 1997. Sirolimus, a new, potent im-munosuppressive agent. Pharmacotherapy 17: 1148-1156.
2. Kahan, B.D. 2001. Sirolimus (RAPAMUNE): A comprehensive review. Expert Opin. Pharmacother. 2: 1903-1917.
3. Nashan, B. 2001. Proliferation signal inhibitors: everolimus (Certican). Transplant. Proc. 33: 3215-3220.
4. Carlson, R.P. et al. 1993. Rapamycin, a potential disease-modifying anti-arthritis drug. J. P h a r m a c o l . Exp. Ther. 266: 1125-1138.
5. Carlson, R.P. et al. 1998. Sirolimus (rapamycin, Ra-pamune) and combination therapy with cyclosporin A in the rat developing adjuvant arthritis model: correlation with blood levels and the effect of different oral formulations. Inflamm. Res. 47: 339-344.
6. Migita, K. et al. 1997. Effects of rapamycin on apop-tosis of rheumatoid synovial cells. Clin. Exp. Immunol. 108: 199-203. (Pubitemid 27223454)
7. Yoon, K.H. 2006. Experience with sirolimus, a new immunosuppressive drug, in 27 Asian patients with resistant/relapsed rheumatic diseases. [abstract] APLAR J. Rheuma. 9: A147 P308.
8. Reitamo, S. et al. 2001. Efficacy of sirolimus (ra-pamycin) administered concomitantly with a subther-apeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br. J. Derm. 145: 438-445.
9. Nadiminti, U. & J.L. Arbiser. 2005. Rapamycin (sirolimus) as a steroid-sparing agent in dermato-myositis. Am. Acad. Derm. 52: S17-19.
10. Bruyn, G.A.W. et al. 2007. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: A 3-month, double-blind, randomized, placebo-controlled, parallel-group, proof-of-concept study. Ann. Rheum. Dis. 67: 1090-1095.
11. Wali, R.K. et al. 2008. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr. Opin. Organ. Transplant. 13: 614-621.
12. Pascual, J. et al. 2006. Everolimus (Certican) in renal transplantation: a review of clinical data, current usage, and future directions. Tr a n s p l a n t . R e v . 20: 1-18.
13. Raichlin, E. et al. 2008. Proliferation signal inhibitors and cardiac allograft vasculopathy. Curr. Opin. Organ. Tr a n s p l a n t . 13: 543-550.
14. Baldo, P. et al. 2008. MTOR pathyway and mTOR inhibitors as agents for cancer therapy. Curr. Opin. Organ. Transplant. 8: 647-665.